Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,54 USD | -1,28% | 0,00% | +79,28% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 129 mln. 120 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -104 mln. -97,14 mln. | Nettowinst (verlies) 2025 * | -107 mln. -99,95 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,8
x | K/w-verhouding 2025 * |
-4,05
x | Werknemers | 138 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,11% |
Recentste transcriptie over NGM Biopharmaceuticals, Inc.
1 dag | -1,28% | ||
Lopende maand | -3,14% | ||
1 maand | -0,65% | ||
3 maanden | +18,46% | ||
6 maanden | +69,60% | ||
Lopend jaar | +79,28% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Woodhouse
CEO | Chief Executive Officer | 54 | 02-03-15 |
William Rieflin
CHM | Chairman | 64 | 01-09-10 |
Daniel Kaplan
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-08 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Roger Perlmutter
BRD | Director/Board Member | 71 | 08-06-21 |
David Goeddel
BRD | Director/Board Member | 72 | 01-01-08 |
William Rieflin
CHM | Chairman | 64 | 01-09-10 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.04% | 0 M€ | 0,00% | - | |
0.02% | 0 M€ | 0,00% | - | |
0.00% | 9 M€ | -.--% | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+79,28% | 129 mln. | |
-0,49% | 103 mld. | |
+3,31% | 96,73 mld. | |
+1,66% | 21,31 mld. | |
-16,16% | 21,21 mld. | |
-6,82% | 18,79 mld. | |
-41,41% | 16,37 mld. | |
-22,87% | 13,68 mld. | |
+6,32% | 13,44 mld. | |
+21,46% | 10,98 mld. |